Printer Friendly
The Free Library
5,665,402 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

IVAX' Veterinary Subsidiary Appoints Kwochka Vice President Research & Development.


Business Editors/Health/Medical Writers

MIAMI--(BUSINESS WIRE)--April 2, 2003

DVM DVM Doctor of Veterinary Medicine.

DVM
abbr.
Doctor of Veterinary Medicine



DVM

Doctor of Veterinary Medicine.
 Pharmaceuticals, Inc., a wholly owned subsidiary Wholly Owned Subsidiary

A subsidiary whose parent company owns 100% of its common stock.

Notes:
In other words, the parent company owns the company outright and there are no minority owners.
 of IVAX Corporation (AMEX AMEX

See: American Stock Exchange
:IVX) (LSE:IVX.L), announces the appointment of Kenneth W. Kwochka, DVM as vice president research & development. Dr. Kwochka will report to Dr. Jane Hsiao, chairman and CEO of DVM Pharmaceuticals, and vice chairman, technical affairs of IVAX Corporation.

Dr. Kwochka is a Diplomate dip·lo·mate
n.
One who has received a diploma, especially a physician certified as a specialist by a board of examiners.


diplomate
(dip´l
 of the American College of Veterinary Dermatology. Dr. Kwochka was an Associate Professor of Medicine/Dermatology at the College of Veterinary Medicine, Department of Veterinary Clinical Sciences at the Ohio State University Ohio State University, main campus at Columbus; land-grant and state supported; coeducational; chartered 1870, opened 1873 as Ohio Agricultural and Mechanical College, renamed 1878. There are also campuses at Lima, Mansfield, Marion, and Newark.  for over 15 years. Dr. Kwochka brings extensive research experience in veterinary medicine from academia, private practice and as a consultant for leading industry drug manufacturers.

DVM Pharmaceuticals is engaged in the research, manufacture, sales and marketing of veterinary pharmaceuticals for companion animals. DVM has been a pioneer and leader in veterinary dermatology products, and has expanded into other therapeutic categories. DVM is also involved in the research and development of proprietary veterinary medicines that capitalize upon the patented technologies and R&D pipeline of those IVAX subsidiaries specializing in drug products for humans.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Apr 2, 2003
Words:192
Previous Article:Coca-Cola Enterprises Delivers First-Quarter 2003 Volume Growth of 2 1/2 Percent; Management Affirms Full-Year 2003 Financial Outlook.
Next Article:Queench to Sponsor SEO-Sponsors for Educational Opportunity Mentor Awards in New York City on April 2nd.
Topics:



Related Articles
IVAX Corporation Names Marcus Vice President, Oncology and Biotechnology.
IVAX Names Gabaroni Business Director for Latin America.
IVAX PREVAILS OVER BRISTOL-MEYERS SQUIBB IN U.K. PATENT RULING.
IVAX Names Lopez Vice President of Human Resources.
IVAX Announces Vice President of Finance for Its Zenith Goldline Subsidiary.
IVAX Appoints Vice President - Strategic Planning and Treasurer.
IVAX BEGINS PHASE II STUDY FOR BPH DRUG.
IVAX Names Marcus Senior Vice President For IVAX Research.
IVAX Names Weiner Senior Vice President For IVAX Research.
IVAX Names New President Of IVAX Laboratories.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles